Spoken Alpha
OABIW
OmniAb, Inc.
Overview
OmniAb licenses antibody discovery technology platforms to pharmaceutical, biotechnology, and academic partners to accelerate identification of therapeutic antibody candidates.
OmniAb, Inc.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
History
Earnings history
Reported quarters with consensus, surprise, and 1-day reaction context.
Track Record
SampleSpoken Alpha tracks OABIW's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 70% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.99 | $3.20 | +24.8% | +5.1% | +5.4% |
| Q4 FY2026 | $4.00 | $3.25 | +23.2% | +0.7% | -1.6% |
| Q3 FY2026 | $3.95 | $3.24 | +21.8% | +6.1% | +7.5% |
| Q2 FY2026 | $3.88 | $3.17 | +22.3% | -3.5% | -5.8% |
| Q1 FY2025 | $4.04 | $3.26 | +23.8% | +4.3% | +3.6% |
| Q4 FY2025 | $3.99 | $3.09 | +29.0% | -2.9% | -0.4% |
| Q3 FY2025 | $4.02 | $3.26 | +23.4% | -3.2% | -1.8% |
| Q2 FY2025 | $4.06 | $3.19 | +27.4% | +5.5% | +6.4% |
| Q1 FY2024 | $4.39 | $3.41 | +28.7% | +1.8% | +2.9% |
| Q4 FY2024 | $4.10 | $3.43 | +19.4% | +3.7% | +1.4% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Matthew W FoehrCEO1 yr 4 mo14 callsCurrentSample
CEO since 2025 • 3/4 beats (75%) • last guidance raise Q2 FY2026
- Kurt A GustafsonCFO1 yr 4 mo14 callsCurrentSample
CFO since 2025 • 2/4 beats (50%) • last guidance raise Q2 FY2026
- Charles S BerkmanChief Legal Officer1 yr 2 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 1/4 beats (25%) • guidance suspended Q2 FY2026
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for OABIW.
$ curl https://api.spokenalpha.com/v1/companies/OABIWFAQ
Frequently asked about OABIW
Where can I find OmniAb, Inc.'s (OABIW) earnings call transcripts?
Spoken Alpha indexes OABIW's earnings call transcripts at https://spokenalpha.com/companies/OABIW. Each call links to attributed speakers and parsed analyst Q&A. OmniAb, Inc.'s own investor relations page is at https://investors.omniab.com/overview/default.aspx.